Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part, Double-Blind, Placebo-Controlled, Phase I Study of the Safety Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Two-Part, Double-Blind, Placebo-Controlled, Phase I Study of the Safety Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zervimesine (Primary)
  • Indications Cognition disorders
  • Focus Adverse reactions; First in man
  • Sponsors Cognition Therapeutics

    • Most Recent Events

    • 19 Feb 2019 According to a Cognition Therapeutics media release, top-line results from the study had been presented at the 9th Annual Clinical Trials on Alzheimer's Disease (CTAD) meeting.
    • 19 Feb 2019 According to a Cognition Therapeutics media release, final results from the study were published in Alzheimer's & Dementia: Translational Research & Clinical Interventions.
    • 19 Feb 2019 Final results published in a Cognition Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top